RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. (“Biogen”) (NASDAQ: BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Biogen’s ...

Upcoming community events will inform plans to create more equitable flying experiences for passengers with reduced mobility CAMBRIDGE, Mass. and ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Delta Flight Products (DFP), a wholly-owned subsidiary of Delta Air Lines established to create aircraft interior solutions to airlines around the world, announced that the companies will collaborate to inform future enhancements to the air travel journey for passengers with reduced mobility. ...

Core Viewpoint - Biogen Inc. and Delta Flight Products are collaborating to enhance air travel accessibility for passengers with reduced mobility, particularly those using wheelchairs, aiming to create a more equitable flying experience [1][2]. Group 1: Collaboration Details - The partnership will involve community events to gather insights from individuals with rare disease mobility restrictions, focusing on their travel experiences and needs [2]. - The first event will take place at the Cure SMA's 2024 Annual SMA Conference from June 6-9, 2024, in Austin, Texas, where feedback will be collected and shared publicly [2][3]. Group 2: Innovations and Products - Delta Flight Products has developed a prototype airplane seat that allows passengers to remain in their own wheelchairs during the flight, addressing a significant gap in travel accessibility [3][4]. - The innovative seat design includes features for comfort and safety, such as adjustable headrests and tray tables, and has received the APEX 2024 Innovation Award for Best Cabin [4]. Group 3: Company Backgrounds - Biogen is a leading biotechnology company focused on innovative treatments for patients with neuromuscular diseases, emphasizing independence and accessibility [5]. - Delta Flight Products specializes in aircraft interior solutions, providing engineering and manufacturing services to enhance airline cabin designs [8].

NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) ...

Jeito Capital announces the acquisition by Merck & Co (NYSE:MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio's novel late-phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases - Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024 The acquisition by Merck & Co (NYSE:MRK), a global biopharmaceutical c ...

Earnings Performance - Biogen reported Q1 2024 adjusted EPS of $3.67, beating the Zacks Consensus Estimate of $3.45, representing an 8% YoY increase driven by cost savings and margin improvements [2] - Total revenues were $2.29 billion, down 7% YoY on both reported and constant-currency basis, missing the Zacks Consensus Estimate of $2.32 billion [2] - Product sales declined 3% YoY to $1.71 billion, with anti-CD20 therapeutic programs revenues down 1% to $394.0 million [2] Key Product Performance - MS revenues declined 4% YoY to $1.08 billion due to generic competition for Tecfidera and rising competitive pressure [4] - Tecfidera sales declined 7.4% to $254.3 million but beat estimates, with EU market protection extended until February 2025 [4] - Vumerity sales increased 18% to $127.5 million, while Tysabri sales declined 9% to $431.3 million [5] - Spinraza sales declined 23% to $341.3 million, with U.S. sales up 1% but ex-U.S. sales down 35% [7] - Skyclarys generated $78.0 million in sales, with 1,100 patients on therapy in the U.S. and 300 in Europe [8] New Product Launches - Leqembi sales nearly tripled sequentially to $19 million in Q1 2024, with patient numbers increasing 2.5 times since 2023-end [3] - Biogen plans to expand its U.S. salesforce by 30% to promote Leqembi as patient volume accelerates [3] - Qalsody recorded $4.6 million in sales, showing encouraging uptake for ALS treatment [8] Cost Management - R&D expenses declined 22% YoY to $447 million, while adjusted SG&A expenses declined 6% to $569 million [10] - Collaboration profit-sharing was a net expense of $66 million, including $61 million related to biosimilar collaboration with Samsung Bioepis [10] Financial Position - No shares were repurchased in Q1 2024, with $2.1 billion remaining under the $5 billion share buyback plan authorized in October 2020 [11] 2024 Guidance - Total revenues expected to decline by low-to mid-single-digit percentage in 2024 [12] - Core pharmaceutical revenues expected to be flat in 2024, with MS revenue declines offset by new product growth [13] - Adjusted EPS expected in the range of $15.00 to $16.00, implying ~5% growth at midpoint [13] - Combined R&D and SG&A expenses expected to be ~$4.3 billion in 2024 [13] - Operating income expected to grow at low-double-digit percentage, with operating margin increasing by mid-single-digit percentage points [13]

NEW YORK, May 23, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers.Class Definition:This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securi ...

LOS ANGELES, May 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are en ...